Table 2 Characterization of C-mannosyltryptophan and Pseudouridine.
Targeted LC/MS measurements | N | Mini-mum | Q1 | Median | Q3 | Maxi-mum | Mean(SD) |
|---|---|---|---|---|---|---|---|
Plasma (µmol/L) | |||||||
C-mannosyltryptophan | |||||||
- Non-CKD individuals | 111 | 0.16 | 0.22 | 0.25 | 0.29 | 0.42 | 0.26 (0.05) |
- CKD patients | 328 | 0.23 | 0.51 | 0.67 | 0.86 | 1.92 | 0.72 (0.28) |
Pseudouridine | |||||||
- Non-CKD individuals | 111 | 2.00 | 2.53 | 2.86 | 3.18 | 4.75 | 2.89 (0.52) |
- CKD patients | 329 | 1.91 | 4.41 | 5.44 | 6.59 | 12.9 | 5.67 (1.84) |
Urine (µmol/mmol creatinine) | |||||||
C-mannosyltryptophan | |||||||
- Non-CKD individuals | 111 | 1.66 | 2.67 | 3.37 | 3.89 | 5.08 | 3.39 (0.80) |
- CKD patients | 377 | 2.12 | 3.59 | 4.18 | 4.81 | 10.9 | 4.30 (1.05) |
Pseudouridine | |||||||
- Non-CKD individuals | 111 | 23.6 | 35.1 | 39.7 | 43.2 | 56.6 | 39.7 (6.74) |
- CKD patients | 377 | 21.5 | 29.5 | 33.0 | 37.5 | 61.6 | 33.9 (6.63) |
Fractional excretion (%) | |||||||
C-mannosyltryptophan | |||||||
- Non-CKD individuals | 111 | 51.0 | 65.6 | 70.8 | 77.8 | 107.0 | 71.8 (9.43) |
- CKD patients | 329 | 34.9 | 63.8 | 72.7 | 85.8 | 126.8 | 75.8 (17.4) |
Pseudouridine | |||||||
- Non-CKD individuals | 111 | 56.0 | 68.6 | 76.0 | 82.4 | 100.2 | 76.1 (9.66) |
- CKD patients | 329 | 42.5 | 65.2 | 73.7 | 83.7 | 115.4 | 74.6 (13.5) |
